ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $289,000 | -47.7% | 25,864 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $553,000 | -47.1% | 25,864 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $1,046,000 | -13.1% | 25,864 | 0.0% | 0.00% | -20.0% |
| Q4 2022 | $1,203,000 | -26.9% | 25,864 | -18.5% | 0.01% | -28.6% |
| Q3 2022 | $1,646,000 | +436.2% | 31,735 | +388.4% | 0.01% | +600.0% |
| Q2 2022 | $307,000 | -71.3% | 6,498 | -56.7% | 0.00% | -75.0% |
| Q1 2022 | $1,068,000 | +30.6% | 15,005 | +37.1% | 0.00% | +33.3% |
| Q4 2021 | $818,000 | +233.9% | 10,945 | +153.4% | 0.00% | +200.0% |
| Q3 2021 | $245,000 | +28.9% | 4,320 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $190,000 | -10.8% | 4,320 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $213,000 | +17.0% | 4,320 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $182,000 | -8.1% | 4,320 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $198,000 | -8.8% | 4,320 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $217,000 | -73.4% | 4,320 | -68.2% | 0.00% | -75.0% |
| Q3 2019 | $816,000 | -28.8% | 13,586 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $1,146,000 | -31.8% | 13,586 | -22.8% | 0.01% | -33.3% |
| Q1 2019 | $1,681,000 | +34.8% | 17,601 | 0.0% | 0.01% | +28.6% |
| Q4 2018 | $1,247,000 | -15.9% | 17,601 | +1.4% | 0.01% | 0.0% |
| Q3 2018 | $1,483,000 | -34.6% | 17,357 | -11.3% | 0.01% | -36.4% |
| Q2 2018 | $2,269,000 | +106.5% | 19,575 | +44.1% | 0.01% | +83.3% |
| Q1 2018 | $1,099,000 | +0.6% | 13,586 | -27.0% | 0.01% | +20.0% |
| Q4 2017 | $1,092,000 | +13.0% | 18,613 | -9.8% | 0.01% | 0.0% |
| Q3 2017 | $966,000 | -35.0% | 20,644 | -50.0% | 0.01% | +25.0% |
| Q2 2017 | $1,486,000 | +85.8% | 41,288 | +58.9% | 0.00% | 0.0% |
| Q1 2017 | $800,000 | +27.0% | 25,980 | +16.2% | 0.00% | 0.0% |
| Q4 2016 | $630,000 | +23.3% | 22,355 | +16.4% | 0.00% | +33.3% |
| Q3 2016 | $511,000 | +20.5% | 19,209 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $424,000 | -21.8% | 19,209 | +4.0% | 0.00% | -25.0% |
| Q1 2016 | $542,000 | +35.5% | 18,462 | +52.2% | 0.00% | +100.0% |
| Q4 2015 | $400,000 | +142.4% | 12,127 | +166.2% | 0.00% | +100.0% |
| Q3 2015 | $165,000 | – | 4,556 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |